BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $127.81 Average Target Price from Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have earned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $127.8125.

Several research firms have recently issued reports on BNTX. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Wells Fargo & Company reduced their price objective on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st.

Institutional Trading of BioNTech

Hedge funds have recently bought and sold shares of the business. LBP AM SA grew its position in shares of BioNTech by 4.3% during the 4th quarter. LBP AM SA now owns 368,584 shares of the company’s stock valued at $35,089,000 after acquiring an additional 15,255 shares during the period. Pictet Asset Management Holding SA raised its holdings in shares of BioNTech by 41.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company’s stock worth $8,457,000 after purchasing an additional 26,119 shares during the period. Monaco Asset Management SAM bought a new stake in shares of BioNTech in the 4th quarter worth approximately $1,594,000. Hsbc Holdings PLC purchased a new position in BioNTech in the fourth quarter valued at approximately $4,969,000. Finally, BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $93.09 on Friday. The stock has a market cap of $23.54 billion, a price-to-earnings ratio of -11.89 and a beta of 1.27. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The business’s 50 day moving average is $91.69 and its 200 day moving average is $96.05.

BioNTech declared that its board has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.